You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

B-ALL/MM/NHL

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),

Not yet recruiting
  • Non Hodgkin's Lymphoma
  • TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
  • +2 more
  • Beijing, China
  • +2 more
Aug 23, 2023

Non-hodgkin Lymphoma Trial (HY004)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • HY004
  • (no location specified)
Aug 21, 2023

Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma,B Cell Trial in Hangzhou (Humanized CD19 CAR-T cells)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Non-hodgkin Lymphoma,B Cell
  • Humanized CD19 CAR-T cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital，College of Medicine, Zhejiang Univ
Aug 25, 2020

B-cell Non Hodgkin Lymphoma Trial in Xuzhou (regimen with BTK inhibitor +Anti-CD19 CAR T cells)

Recruiting
  • B-cell Non Hodgkin Lymphoma
  • regimen with BTK inhibitor +Anti-CD19 CAR T cells
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023

Relapsed or Refractory Mantle Cell Lymphoma (MCL) Trial in Duarte (BAFFR-CAR T cells)

Recruiting
  • Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
  • BAFFR-CAR T cells
  • Duarte, California
    City of Hope Medical Center
Oct 18, 2022

Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in

Not yet recruiting
  • Non-Hodgkin Lymphoma, B-cell
  • "novel" MAB (alone or in combination)
  • Viagrande, Catania, Italy
  • +57 more
Aug 18, 2023

Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

Not yet recruiting
  • Advanced Malignancies
  • 1A46 Drug Substance
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 4, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

B-cell Lymphoma Trial in Xuzhou (ASCT+CAR-T Cell Infusion)

Recruiting
  • B-cell Lymphoma
  • ASCT+CAR-T Cell Infusion
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023

CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)

Recruiting
  • CD20-positive B-cell Non-Hodgkin's Lymphoma
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Apr 6, 2023

Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent, Mantle Cell Lymphoma Refractory Trial in Orange,

Recruiting
  • Follicular B-cell Non-Hodgkin's Lymphoma
  • +7 more
  • MB-106
  • Orange, California
  • +3 more
Nov 1, 2022

Lymphoma, Non-Hodgkin Trial in China (DZD8586)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Beijing, Beijing, China
  • +5 more
Apr 25, 2023

Severe COVID-19 Infection in CLL or B-NHL Who Received

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
    • (no location specified)
    Apr 6, 2023

    Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive

    Active, not recruiting
    • Aggressive B-Cell Non-Hodgkin Lymphoma
    • fractionated first dose rituximab
    • Geneva, Switzerland
      University Hospital Geneva
    Apr 21, 2023

    NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia Trial (KUR-502)

    Not yet recruiting
    • NHL, Relapsed, Adult
    • +3 more
    • KUR-502
    • (no location specified)
    Aug 2, 2022

    B-cell NHL, CLL Trial (CARCIK-CD19)

    Not yet recruiting
    • B-cell NHL
    • CLL
    • CARCIK-CD19
    • (no location specified)
    May 19, 2023

    Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • BTK inhibitor
    • PD-1 inhibitor
    • Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    May 20, 2023

    SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:

    Not yet recruiting
    • B-cell Non Hodgkin Lymphoma
    • +2 more
      • (no location specified)
      Jun 22, 2023

      Non-Hodgkin's Lymphoma (Disorder), Acute Lymphoid Leukemia, Disease (Disorder) Trial in Louisville, Houston (1A46 Injection)

      Recruiting
      • Non-Hodgkin's Lymphoma (Disorder)
      • Acute Lymphoid Leukemia, Disease (Disorder)
      • 1A46 Injection
      • Louisville, Kentucky
      • +1 more
      Aug 1, 2022

      Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas Trial (ATG-031)

      Not yet recruiting
      • Advanced Solid Tumors
      • B-cell Non-Hodgkin Lymphomas
      • (no location specified)
      Aug 31, 2023

      B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine

      Not yet recruiting
      • B-cell Non Hodgkin Lymphoma
      • Chronic Lymphocytic Leukemia
      • Cyclophosphamide injection
      • +2 more
      • Charleston, South Carolina
        Hollings Cancer Center at Medical University of South Carolina
      Jan 18, 2023

      B-cell Non-Hodgkin Lymphoma (B-NHL) Trial in Austin (UCART20x22, CLLS52)

      Recruiting
      • B-cell Non-Hodgkin Lymphoma (B-NHL)
      • UCART20x22
      • CLLS52
      • Austin, Texas
        Sarah Cannon - St. David South Austin Medical Center
      Dec 8, 2022

      Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy Trial in United States (Emavusertib, ibrutinib)

      Recruiting
      • Relapsed Hematologic Malignancy
      • Refractory Hematologic Malignancy
      • Phoenix, Arizona
      • +10 more
      Feb 1, 2023

      Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

      Recruiting
      • Diffuse Large Cell Lymphoma
      • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Feb 2, 2023

      B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (IKS03)

      Not yet recruiting
      • B-cell Non-Hodgkin Lymphoma
      • +4 more
      • (no location specified)
      Dec 7, 2022